Methomyl


Curated chemical-gene interactions from CTD
Entrez gene IDGene symbolInteraction typeReference
1158 CKM Increases expression PMID:39742927
1588 CYP19A1 Increases activity PMID:11884232
2488 FSHB Increases expression PMID:11516254
3162 HMOX1 Decreases expression PMID:39742927
3303 HSPA1A Decreases expression PMID:16271832
3309 HSPA5 Increases expression PMID:16271832
3312 HSPA8 Decreases expression PMID:16271832
3939 LDHA Increases expression PMID:39742927
3972 LHB Increases expression PMID:11516254
43 ACHE Decreases activity PMID:19371631; PMID:21251949; PMID:23962483; PMID:33844597; PMID:8134223; PMID:19934164; PMID:21251949; PMID:25707986
4780 NFE2L2 Decreases expression PMID:39742927
4843 NOS2 Decreases expression PMID:39742927
5617 PRL Increases expression PMID:11516254
5743 PTGS2 Decreases expression PMID:39742927
581 BAX Increases expression PMID:34676817
596 BCL2 Decreases expression PMID:34676817
7178 TPT1 Increases expression PMID:30472887
7184 HSP90B1 Decreases expression PMID:16271832
836 CASP3 Increases expression PMID:34676817
847 CAT Decreases expression PMID:39742927
883 KYAT1 Decreases activity PMID:7175100
8942 KYNU Decreases activity PMID:7175100
9817 KEAP1 Increases expression PMID:39742927

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.